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Chemokine-driven migration of inﬂammatory cells has been implicated in pathogenesis of atherosclerosis-associated conditions
suchasischemicstrokeandmyocardialinfarction.Inthisstudy,acandidatechemokine,monocytechemoattractantprotein(MCP)-
1,wasinvestigatedinpatientswithbothaforementionedmanifestationsofatherosleroticinﬂammation.MCP-1levelsinserumwere
determined by ELISA in 40 healthy, control subjects (C), 40 patients with ischemic stroke (IS), and in 64 patients with myocardial
infarction (MI). Statistical analysis utilised Mann-Whitney test, Fisher’s exact test, and Spearman’s rank correlation (P<. 05). In
comparison to control subjects (C; median/interquartile range: 239/126pg/mL), MCP-1 serum levels were increased in both inves-
tigated patient cohorts (IS: 384/370, P<. 001; MI: 360/200, P<. 002). There was a substantial variability of MCP-1 serum levels,
especially in the IS group. No relationship was observed between chemokine levels and atherosclerosis risk factors (hypertension,
diabetes, smoking, and alcohol consumption), and MCP-1 was also not related to age or gender. Elevation of MCP-1 in circulation
of patients with atherosclerosis-associated complications implicates this CC chemokine ligand (CCL)2 in inﬂammatory processes,
which contribute to pathogenesis of myocardial infarction and ischemic stroke. Further investigations, including patient stratiﬁca-
tion, are however necessary to evaluate if MCP-1 can be utilised for clinical management of patients with these diseases.
INTRODUCTION
Ischemic stroke (IS) and myocardial infarction (MI)
are atherosclerosis-associated complications that are the
leading causes of mortality and disability all over the
world [1]. IS and MI share common features, but at
the same time there are diﬀerences in many risk fac-
tors, at least quantitative, if not qualitative. Compared
with myocardial infarction, stroke patients are at least 10
years older, the incidence in middle-aged men compared
with women is smaller, and increasing blood pressure is
more strongly associated with stroke, whereas increasing
plasma cholesterol is less strongly associated with stroke
[2].
Recent studies showed that aberrant immune re-
sponse evolves during both IS and MI that is deleteri-
ous and contributes to cell death after the insults [3,
4, 5]. Both pathologies are characterized by expression
of proinﬂammatory cytokines, adhesion molecules, and
importantly, chemokines that orchestrate the inﬁltration
of leukocytes into infarct area, expression of damaging
agents and activation of complement system (for review
see [6, 7]).
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Chemokines are low molecular weight polypeptides
that, besides other functions, exert potent chemotac-
tic and activating eﬀects on speciﬁc leukocyte popula-
tions [8]. Recently, there has been growing interest in
applications of chemokine biology into clinic, including
atherosclerosis [9]. CC chemokine ligand (CCL)2, more
widely known as monocyte chemoattractant protein-1
(MCP-1), is a potent mononuclear cell attractant [10].
It has been previously implicated in the development of
bothISandMI.Forexample,inanimalexperiments,high
levels of MCP-1 mRNA have been found in the brain 6
hours after cerebral ischemia. The maximal expression
of this chemokine was observed between 12 hours and 2
days [11, 12]. MCP-1 mRNA expression was upregulated
in infarcted area after MI in the same manner like in IS
[13, 14].
Most of the data about cytokine and chemokine in-
volvement in pathogenesis of IS and MI has been derived
from animal studies. Nowadays, more attention is being
paid to studies utilising human subjects. In this context,
blood becomes an invaluable target for such studies, due
to its relative availability. Recently, it has been shown that
the levels of several cytokines are elevated in the blood
of patients with IS and MI [15, 16, 17, 18]. However,
data on MCP-1 are scarce, especially in strokes. We, there-
fore, performed the present study to provide additional
data on involvement of MCP-1 in MI, and namely in IS.176 A. Arakelyan et al 2005:3 (2005)
Doing so, we wished to complement existing studies tar-
geted at evaluation of chemokine inﬂammatory response
in pathogenesis of these two atherosclerosis-associated
complications.
SUBJECTS AND METHODS
Studypopulation
Forty patients with IS (17 female, age [years, mean ±
SD]: 67.5 ±10.5) and 64 patients with MI (8 female, age
55 ±8.8) were entered in the study. Patients with concur-
rent diseases or conditions interfering with the aim of the
study, such as infections, malignancies and those on im-
munosuppressive drugs were excluded from study.
Diagnosis of IS was based on clinical history and neu-
rologicalexaminationandwasconﬁrmedbybrainCT.On
CT examination, all stroke patients presented anatomi-
callyrelevant hypodense areasin subcorticalparts of cere-
bral hemispheres.
Diagnosis of MI was determined from the presence of
> 30 minutes of continuous chest pain, ST-segment ele-
vation > 2.0mm on at least 2 contiguous ECG leads, and
more than a 3-fold increase in serum creatine kinase lev-
els.
Regarding risk factors, 44% of MI and 50% of IS pa-
tients had hypertension, 18% of MI and 9% of IS patients
had diabetes mellitus, 54% of MI and 18% of IS patients
reported themselves as current smokers, and 8% of MI
and 5% of IS patients reported themselves as alcohol con-
sumers. In addition 7% of IS patients previously had is-
chemic heart disease.
Forty healthy subjects (7 female, age 52 ± 3) free of
clinical signs of infection, other systemic diseases, and
negative family history of IS or MI served as control pop-
ulation.
Venous blood samples were obtained from IS and MI
patientswithin24hoursafterdiseaseonsetandoncefrom
controls. Serum samples were stored at −70◦ C until fur-
ther analysis.
ISpatients wererecruited atErebouni MedicalCenter,
Yerevan, Armenia; MI patients were diagnosed at the Fac-
ulty Hospital Olomouc, Czech Republic. All subjects gave
their informed consent to be involved in this study. Local
Ethical Committees approved the study.
DeterminationofMCP-1protein
MCP-1 protein levels in serum obtained from study
participants were measured using a solid-phase sandwich
enzyme-linked immunosorbent assay (MCP-1 Quan-
tikine ELISA kit, R&D systems, Abingdon, UK). Brieﬂy,
100µL of duplicated samples or standards (reeom-
binant human MCP-1) were incubated (2 hours at
room temperature) in the wells precoated with pri-
maryantihumanMCP-1antibody.Afterincubation,wells
were washed three times and horseradish peroxidase-
conjugated polyclonal antibodies against MCP-1 were
added (for 2 hours at room temperature). Finally,
tetramethylbenzidine substrate solution was applied for
30minutes and, after stopping the reactions by 2M sul-
furic acid, the absorbance was measured at 450nm (with
correctionat540nm).ThedatawereevaluatedwithKIM-
Esoftware(USOL,Prague,CzechRepublic);thedetection
limit of the MCP-1 assay was 5.0pg/mL.
Statisticalanalysis
SPSS 11 (SPSS Inc, Chicago, Ill) software was used to
calculate basic statistical parameters and to perform the
Mann-WhitneyU-testtotestfordiﬀerencesinchemokine
protein levels between the MI, IS, and control groups
as well as for further subanalysis. Fisher’s exact test was
used to compare diﬀerences in qualitative parameters be-
tween IS and MI groups. Spearman’s rank correlation was
used to evaluate relationship between age and MCP-1 lev-
els. Data on MCP-1 levels was presented as median [in-
terquartile range (IQR)]. P<. 05 was considered statisti-
cally signiﬁcant.
RESULTS
In this study, MCP-1 immunoreactive protein was de-
termined in peripheral blood of patients with MI and IS.
Priortochemokineanalysis,thediﬀerencesinriskfac-
tors among our study groups were estimated. MI patients
w e r ei na v e r a g e1 2y e a r sy o u n g e r( P<. 0001). Also, there
were diﬀerences in male/female ratio (IS, 42% versus MI,
12%, P<. 0001) and in number of smokers (MI, 54%
versus IS, 18%, P<. 0001). Number of suﬀerers from dia-
betes was 2-fold higher in MI group compared with IS,
but this diﬀerence did not reach signiﬁcance (MI, 18%
versus IS, 9%, P>. 05). The study groups did not diﬀer
with regard to hypertension and alcohol consumption.
Incomparisontocontrolsubjects(median[IQR]:239
[126] pg/mL), the levels of MCP-1 protein were elevated
in patients from both study groups (Figure 1). This in-
crease was more apparent in the IS group (384 [370]
pg/mL), for which also a greater degree of interindivid-
ual variability was observed than among patients with MI
(360 [200] pg/mL). While only 10/40 (25%) of control
subjects had MCP-1 level higher than 314 pg/ml (75th
percentile of the control group), in patients with IS this
proportion reached 68% (27 /40) and in MI group it was
61% (39/64). The diﬀerences between both investigated
patient groups and controls, therefore, reached high sig-
niﬁcance (IS versus C, P<. 001; MI versus C, P<. 002),
while there was no diﬀerence between patients’ groups
themselves (IS versus MI, P>. 05).
Further, we investigated whether MCP-1 protein is in-
ﬂuenced by risk factors of MI and IS. Serum chemokine
levels were compared between patients with and with-
outdiabetes,hypertension;smokersandnonsmokers;and
also groups divided based on alcohol consumption. Data
analysis showed that none of the above risk factors had an
inﬂuence at circulating MCP-1 levels in patients with MI
and/or IS (Table 1). Furthermore no gender eﬀect MCP-12005:3 (2005) MCP-1 in Ischemic Stroke and Myocardial Infarction 177
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Figure 1. Monocyte chemoattractant protein (MCP)-1 levels
(pg/mL) in serum of patients with myocardial infarction (MI,
n = 64), ischemic stroke (IS, n = 40), and healthy, control sub-
jects (n = 40). The data are expressed as whisker box plots; the
box represents the 25–75th percentiles, the median is indicated
by a bar across the box, the whiskers on each box represent the
10–90th percentiles. ∗ P<. 002 when comparing with the con-
trol group.
l e v e l sw a sa p p a r e n ti nb o t hs t u d i e dg r o u p sa sw e l la si n
control group (IS males versus females: 417 [400] versus
253 [296], P>. 05; MI males versus females: 343 [203]
versus 397 [300], P>. 05; C males versus females: 244
[125] versus 234 [93], P>. 05), and there was no cor-
relation between age and the chemokine levels (IS: rs =
−0.009, P>. 05, MI: rs =− 0.06, P>. 05, C: rs = 0.168 ,
P>. 05).
DISCUSSION
This study aimed at the evaluation of the MCP-1
chemokine in the circulation of patients with myocardial
infarction and ischemic stroke. These two atherosclerosis-
associated complications share many similarities, but at
the same time they have at least quantitative if not qual-
itative diﬀerences in their risk factors [2]. This trend is
preserved in our patients’ characteristics: our IS patients
were older and the diﬀerent incidence in males and fe-
m a l e si sl e s sp r o n o u n c e di nI Sc o m p a r e dt oM I .A l s o ,I S
patients were more prone to hypertension than MI pa-
tients. Presence of these features, therefore, conﬁrms that
our patients’ groups were properly created and reﬂect the
actual situation with IS and MI phenotypes. This fact is
important for interpretation of chemokine data.
Our data showed almost 2-fold increase of serum
MCP-1 levels in patients with MI and IS compared with
control group of healthy subjects. We also found that
serum MCP-1 levels did not diﬀer between IS and MI pa-
tients. Finally, the levels of this chemokine were not inﬂu-
enced by known risk factors for these diseases such as hy-
pertension, diabetes, smoking, or alcohol consumption.
In myocardial infarction, elevation of circulating
MCP-1 has been already reported [19, 20, 21] and, there-
fore,ourﬁndingsofincreasedMCP-1inourpatientswith
MI are of a conﬁrmatory nature. However, infrequent
reports regarding this chemokine in ischemic stroke are
contradictory [22, 23]. Losy and Zaremba [22]r e p o r t e d
that blood MCP-1 levels were not increased in his group
of 23 patients with IS. By contrast and in line with our
results, Reynolds et al [23] demonstrated elevation of the
MCP-1 chemokine in the blood from a big group of more
than 200 stroke patients. This discrepancy may occur due
to low number of subjects included in the study by Losy
and Zaremba [22] and possibly also by marked variability
of circulating MCP-1 levels.
There are at least two mechanisms by which the ob-
served upregulation of MCP-1 protein levels in circula-
tion of patients with IS and MI can be achieved. Firstly,
it may be the direct consequence of atherosclerosis devel-
opment. The main sources of MCP-1 are endothelia and
macrophage like cells [24], which are known to play a sig-
niﬁcant role in atherosclerosis development and plaque
formation. In vitro studies have revealed that endothelial
cells are able to produce MCP-1 in response to LDL an
important atherosclerosis triggering factor [25, 26].
Second, increased MCP-1 levels can mirror the de-
velopment of inﬂammatory response in heart and brain.
Numerous studies on animal models of stroke showed
that MCP-1 and MIP-1beta are two main chemokines
that orchestrate inﬁltration of blood-derived monocytes
and lymphocytes into ischemic area. The upregulation
o fM C P - 1m R N Al e v e l si sd e t e c t e di nb o t hp e r m a n e n t
and transient models of focal ischemia [11, 12]. Moreover
study by Hughes et al [27] demonstrated that MCP-1 de-
ﬁciency is protective in a murine stroke model. The same
processes are taking place in heart during MI [13, 14].
Furthermore, it has been demonstrated that mice lacking
CCR2, the primary receptor for MCP-1, showed signif-
icant impairment of monocyte inﬁltration, reduction of
TNF-alpha, and matrix metalloproteinases expression in
infarcted area in experimental MI [28].
Our data showed that elevation of MCP-1 in the
blood is a common feature for MI and IS. This may sug-
gest that in atherosclerosis-associated complications, in-
ﬂammatory response, share some similarities and are not
organ-speciﬁc. This interpretation ﬁts in with other cur-
rent reports [29, 30, 31], including our recent observation
ofapproximately2-foldincreaseofMCP-1inthebloodof
patients with peripheral arterial disease [32].
Unexpectedly, in our study none of four investigated
common risk factors for MI and IS did not inﬂuence
serum MCP-1 levels. In number of previous studies in pa-
tientswithmyocardialinfarction,theassociationofMCP-
1 levels with several risk factors such as hypertension [33]
and diabetes [20] has been reported. However, these were
large-population-based studies where even slight diﬀer-
ences may be identiﬁed. For example, in the study by de
L e m o se ta l[ 20] more than 2000 subjects were enrolled
and thus the authors were able to identify a rather mi-
nordiﬀerenceof6%assigniﬁcant.Itis,therefore,possible
thatinourrelativelysmallpatientpopulationof64MIpa-
tients,diﬀerencesofsimilarmagnitudemaynotbevisible.
Regarding patients with ischemic stroke, there have been178 A. Arakelyan et al 2005:3 (2005)
Table 1. Diﬀerences in MCP-1 levels (pg/mL) in the serum of patients with IS and MI reﬂecting the presence (+) or absence (−)o f
known risk factors.
MI patients IS patients
Hypertension + Hypertension − Hypertension + Hypertension −
365/188 379/256 384/384 394/302
Diabetes + Diabetes − Diabetes + Diabetes −
380/262 371/199 396/283 380/244
Smoking + Smoking − Smoking + Smoking −
353/203 400/318 396/303 380/213
Alcohol + Alcohol − Alcohol + Alcohol −
576/346 365/211 387/237 302/223
no studies on inﬂuence of risk factors on MCP-1 levels.
We, therefore, plan to further explore this phenomenon
so that it can be assessed if monitoring MCP-1 serum lev-
els can be included into the algorithm of management of
IS patients as an independent marker.
In conclusion, our data expand previous observations
showing that MCP-1 plays an important role in inﬂam-
matory response developing during myocardial infarction
and ischemic stroke. Further work is, however, necessary
to deﬁne more precisely the relationship between MCP-
1 and clinical course of investigated diseases. Emphasis
shouldbegiventopatients’stratiﬁcationinordertoascer-
tain clinical utilisation of MCP-1 measurements, namely
in ischemic stroke.
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